ALKEON CAPITAL MANAGEMENT LLC 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-13 09:45 am Sale | 2024-09-30 | 13G | Akero Therapeutics, Inc. AKRO | ALKEON CAPITAL MANAGEMENT LLC | 3,325,004 4.800% | -439,216 (-11.67%) | Filing |
| 2024-02-13 6:30 pm Purchase | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | ALKEON CAPITAL MANAGEMENT LLC | 3,764,220 6.800% | 520,305 (+16.04%) | Filing |
| 2023-02-13 10:54 am Purchase | 2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO | ALKEON CAPITAL MANAGEMENT LLC | 3,243,915 6.900% | 764,244 (+30.82%) | Filing |
| 2022-02-11 8:25 pm Purchase | 2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO | ALKEON CAPITAL MANAGEMENT LLC | 2,479,671 7.100% | 192,041 (+8.39%) | Filing |
| 2021-02-11 4:54 pm Purchase | 2020-12-31 | 13G | Akero Therapeutics, Inc. AKRO | ALKEON CAPITAL MANAGEMENT LLC | 2,287,630 6.600% | 2,287,630 (New Position) | Filing |